BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18430894)

  • 1. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
    Arlot-Bonnemains Y; Baldini E; Martin B; Delcros JG; Toller M; Curcio F; Ambesi-Impiombato FS; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2008 Jun; 15(2):559-68. PubMed ID: 18430894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Catania A; Moretti C; Mocini R; Carbotta G; Morrone S; Persechino S; Redler A; De Antoni E; D' Armiento M; Ulisse S
    J Biol Regul Homeost Agents; 2013; 27(3):705-15. PubMed ID: 24152827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
    Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
    Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues.
    Ulisse S; Baldini E; Toller M; Delcros JG; Guého A; Curcio F; De Antoni E; Giacomelli L; Ambesi-Impiombato FS; Bocchini S; D'Armiento M; Arlot-Bonnemains Y
    Endocr Relat Cancer; 2007 Sep; 14(3):827-37. PubMed ID: 17914111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity.
    Ulisse S; Arlot-Bonnemains Y; Baldini E; Morrone S; Carocci S; Di Luigi L; D'Armiento M
    J Endocrinol; 2010 Feb; 204(2):135-42. PubMed ID: 19889886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
    Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S
    BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.
    Xu DR; Huang S; Long ZJ; Chen JJ; Zou ZZ; Li J; Lin DJ; Liu Q
    J Transl Med; 2011 May; 9():74. PubMed ID: 21600017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma.
    Wan XB; Fan XJ; Chen MY; Xu J; Long ZJ; Hua YJ; Ji H; Liu L; Hong MH; Zeng YX; Liu Q
    Cancer Biol Ther; 2009 Aug; 8(15):1500-6. PubMed ID: 19502819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
    Gizatullin F; Yao Y; Kung V; Harding MW; Loda M; Shapiro GI
    Cancer Res; 2006 Aug; 66(15):7668-77. PubMed ID: 16885368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.
    Pan C; Yan M; Yao J; Xu J; Long Z; Huang H; Liu Q
    Oral Oncol; 2008 Jul; 44(7):639-45. PubMed ID: 17996488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Walsby E; Walsh V; Pepper C; Burnett A; Mills K
    Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.
    Harrington EA; Bebbington D; Moore J; Rasmussen RK; Ajose-Adeogun AO; Nakayama T; Graham JA; Demur C; Hercend T; Diu-Hercend A; Su M; Golec JM; Miller KM
    Nat Med; 2004 Mar; 10(3):262-7. PubMed ID: 14981513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.
    Huang XF; Luo SK; Xu J; Li J; Xu DR; Wang LH; Yan M; Wang XR; Wan XB; Zheng FM; Zeng YX; Liu Q
    Blood; 2008 Mar; 111(5):2854-65. PubMed ID: 18160664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
    Tyler RK; Shpiro N; Marquez R; Eyers PA
    Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
    Wunderlich A; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
    Endocrine; 2012 Dec; 42(3):637-46. PubMed ID: 22477151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targeted therapies for anaplastic thyroid cancer.
    Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
    Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.